AACR: Cadonilimab Plus Chemo Beneficial for Gastric Adenocarcinoma
By Elana Gotkine HealthDay Reporter
MONDAY, April 8, 2024 -- For patients with gastric/gastroesophageal junction (G/GEJ) adenocarcinoma, cadonilimab plus chemotherapy is associated with improved overall survival and progression-free survival, according to a study presented at the annual meeting of the American Association for Cancer Research, held from April 5 to 10 in San Diego.
Jiafu Ji, M.D., Ph.D., from the Gastrointestinal Cancer Center at Peking University Cancer Hospital & Institute in Beijing, and colleagues conducted a randomized, placebo-controlled trial involving adults with untreated, unresectable, locally advanced, or metastatic G/GEJ adenocarcinoma, regardless of PD-L1 expression. Patients from 76 study centers were randomly assigned to cadonilimab plus chemotherapy or placebo plus chemotherapy (305 patients to each group), with a median follow-up of 18.69 months.
The researchers found median overall survival to be longer in the cadonilimab versus the placebo group (15.0 versus 10.8 months; hazard ratio, 0.62). At all prespecified combined positive score cutoffs, overall survival benefits were consistently observed, especially in patients with low PD-L1 expression. The cadonilimab group had longer progression-free survival (median, 7.0 versus 5.3 months; hazard ratio, 0.53). Grade ≥3 treatment-related adverse events occurred in 71.8 and 60.5 percent of patients who received cadonilimab and placebo, respectively; there were no new safety events reported.
"These findings may change the current practice of gastric cancer treatment," Ji said in a statement. "Cadonilimab combined with chemotherapy could become a new standard of care in first-line treatment of gastric cancer, even for patients with low PD-L1 expression."
The study was funded by Akeso Biopharma, the manufacturer of cadonilimab.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted April 2024
Read this next
Recommendations Issued for Palliative RT for Symptomatic Bone Mets
THURSDAY, May 30, 2024 -- In a clinical practice guideline issued by the American Society for Radiation Oncology and published online May 22 in Practical Radiation Oncology...
Living Outside of Comprehensive Cancer Center Catchment Area Tied to Later-Stage Diagnosis
TUESDAY, May 28, 2024 -- Disadvantaged populations and those living outside of a comprehensive cancer center's main catchment area have higher odds of receiving a diagnosis of...
Disparities Seen in Cancer Treatment Delivery at Minority-Serving Hospitals
TUESDAY, May 28, 2024 -- There are systemic disparities in definitive cancer treatment delivery at minority-serving hospitals (MSHs) versus non-MSHs, according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.